A pharmaceutical composition comprising at least one protein kinase inhibitor and a stable amorphous hybrid nanoparticles of at least one polymeric stabilized matrix forming ingredient

摘要

Problem to be solved: to provide a new pharmaceutical composition capable of improving the bioavailability and stability of the pharmacological active component in the pharmaceutical composition containing the water-soluble drug.Solution comprises at least one protein kinase inhibitor (nylonitib, etc.) and a stable amorphous solid dispersion particle of at least one polymeric stabilized matrix forming ingredient, optionally A pharmaceutical composition comprising at least one pharmacologically acceptable solubilizer.No selection